AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24918721
Drug: Topical policresulen
RxNorm normalized name: policresulen
DrugBank: Policresulen (DB13492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical policresulen + cinchocaine
Trial: 24918721
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual guidelines with oral medications)
Trial: 12209517
Drug: Low-dose IV
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IV CYC (500 mg, 6 fortnightly pulses) followed by AZA
Trial: 12209517
Drug: High-dose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IV CYC (6 monthly pulses and 2 quarterly pulses, doses increased according to WBC count) followed by AZA
Trial: 25063793
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg once daily)
Trial: 25063793
Drug: GTN (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN (0.6 mg/h, 2 h/day)
Trial: 2053453
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg of elemental calcium supplementation
Trial: 12010667
Drug: High-dose UFH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose UFH (12,500 IU for one week followed by 10,000 IU)
Trial: 7644088
Drug: Ketanserin 20-40
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 20-40 mg bid for three weeks
Trial: 7644088
Drug: Enalapril 10-20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10-20 mg bid for three weeks
Trial: 23500313
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose of diuretics
Trial: 12632341
Drug: High-dose cisplatin-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin-based chemotherapy (HDPEB)
Trial: 18555147
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (both groups)
Trial: 31869430
Drug: Glyburide/Metformin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide/Metformin combination therapy (COMBO)
Trial: 31869430
Drug: Metformin (MET)
RxNorm normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MET) and Glyburide/Metformin combination therapy (COMBO)
Trial: 27733219
Drug: Ultrasound-guided TAP
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided TAP block with 0.5% ropivacaine 20 ml at 30 minutes before surgery
Trial: 10957661
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin injections (HEP group)
Trial: 10957661
Drug: Thigh-length sequential
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thigh-length sequential EPC device (EPC group)
Trial: 10957661
Drug: Both subcutaneous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both subcutaneous heparin injections and EPC device (HEP + EPC group)
Trial: 9285071
Drug: B13/L2 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B13/L2 supplementation (13 mg beta-carotene, 2 mg lycopene, 5 mg vitamin E, 30 mg vitamin C)
Trial: 9285071
Drug: B3/L3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B3/L3 supplementation (3 mg beta-carotene, 3 mg lycopene, 5 mg vitamin E, 30 mg vitamin C)
Trial: 20170481
Drug: Removable dental
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removable dental prostheses for molar replacement (treatment A)
Trial: 20170481
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments A and B
Trial: 18498925
Drug: Erlotinib added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib added to gemcitabine treatment regimen for 40% (n=10) of gemcitabine-treated patients for 15.7 weeks of therapy
Trial: 18498925
Drug: Erlotinib added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib added to gemcitabine treatment regimen
Trial: 10813547
Drug: Drug/polymer system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug/polymer system
Trial: 6383692
Drug: High-dose naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose naloxone infusion during severe exercise
Trial: 6383692
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion during severe exercise
Trial: 6682026
Drug: Naloxone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone infusion
Trial: 31674256
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment (CT) group with low-dose dexamethasone (5mg/d) for 5 days
Trial: 27451942
Drug: ESAT6‐CFP10 (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESAT6‐CFP10 (0.1, 0.5, 1 or 2 μg)
Trial: 17687925
Drug: VEGF inhibitors
RxNorm normalized name: Vegf receptor 2 kinase inhibitor i
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGF inhibitors (pegaptanib, ranibizumab, bevacizumab)
Trial: 15158629
Drug: Elemental zinc
RxNorm normalized name: Zinc, 220 mg (as elemental zinc 50 mg) oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental zinc (20 mg per day)
Trial: 9040630
Drug: Glucose-insulin-potassium solution
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium solution (30% dextrose in water; K+, 80 mEq/L; regular insulin, 50 units) given intravenously at 1 ml/kg per hour for 12 hours after aortic unclamping
Trial: 9040630
Drug: Glucose-insulin-potassium solution
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium solution
Trial: 23230756
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of autologous platelet-rich gel (APG)
Trial: 12745511
Drug: 300mg bupropion
RxNorm normalized name: bupropion hydrochloride 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg bupropion SR + 21 mg/24-hr nicotine patch
Trial: 12504657
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) 10 mg/m2 on day 1 and continuous infusion of 5-fluorouracil (5-FU) 200 mg/m2 from days 1-26 in the first sequence (36 Gy over 4 weeks) and 5-FU 200 mg/m2 from days 1-17 in the second sequence (23.4 Gy over 17 days)
Trial: 18341673
Drug: Brivaracetam 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 400 mg/day
Trial: 20392617
Drug: 1 portion
RxNorm normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 portion of fruit and vegetable (FV) daily for 8 weeks
Trial: 20392617
Drug: 3 portions
RxNorm normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 portions of fruit and vegetable (FV) daily for 8 weeks
Trial: 20392617
Drug: 6 portions
RxNorm normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 portions of fruit and vegetable (FV) daily for 8 weeks
Trial: 17130849
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg lidocaine per nostril
Trial: 17130849
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lidocaine per nostril
Trial: 17130849
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg lidocaine per nostril
Trial: 15101566
Drug: Sulpiride augmentation
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride augmentation (600 mg/day) with olanzapine
Trial: 31818823
Drug: Gepotidacin 750
RxNorm normalized name: gepotidacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepotidacin 750 mg every 12 hours (q12h)
Trial: 17577103
Drug: Duloxetine 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 120 mg BID
Trial: 17577103
Drug: Duloxetine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 200 mg BID
Trial: 17577103
Drug: Duloxetine 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 160 mg BID
Trial: 9522134
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine (50 mg) intra‐articular (IA)
Trial: 2478604
Drug: 10 or
RxNorm normalized name: K-10 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 or 100 times the concentration of allergen required for 4+ early intradermal reaction
Trial: 799983
Drug: Betamethasone-17, 21-dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone-17, 21-dipropionate and salicylic acid treatment
Trial: 31502392
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream (TCC) (hydroquinone 2% + tretinoin 0.025% + fluocinolone acetonide 0.01%)
Trial: 31605113
Drug: RSV/ΔNS2/Δ1313/I1314L vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV/ΔNS2/Δ1313/I1314L vaccine at 106 PFU
Trial: 31605113
Drug: RSV/ΔNS2/Δ1313/I1314L vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV/ΔNS2/Δ1313/I1314L vaccine at 105 PFU
Trial: 27756788
Drug: Urelumab 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urelumab 0.1 mg/kg every 3 weeks
Trial: 27756788
Drug: Urelumab doses
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Urelumab doses between 1 and 15 mg/kg every 3 weeks
Trial: 27756788
Drug: Urelumab doses
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Urelumab doses ≥1 mg/kg
Trial: 24283127
Drug: Gel beads
RxNorm normalized name: Bead Tree Leaf
DrugBank: Azadirachta indica leaf (DB14352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel beads containing Eimeria oocysts
Trial: 24283127
Drug: Spray vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray vaccination with Eimeria oocysts
Trial: 24283127
Drug: Gel beads
RxNorm normalized name: Bead Tree Leaf
DrugBank: Azadirachta indica leaf (DB14352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel beads or spray vaccination
Trial: 12742981
Drug: VEGF plasmid
RxNorm normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGF plasmid liposome (VEGF‐P/L; 2000 microg of DNA with 2000 microL of DOTMA:DOPE [1:1 wt/wt])
Trial: 8769695
Drug: Hydroxyurea monotherapy
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea monotherapy
Trial: 10669337
Drug: Didanosine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine monotherapy
Trial: 28561068
Drug: GHB (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB (35 mg/kg p.o.)
Trial: 24446590
Drug: Conventional gingival
RxNorm normalized name: Bos taurus gingiva preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional gingival displacement (gingival cord + 25% AlCl3 astringent gel)
Trial: 22562021
Drug: Adalimumab high
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab high dose (40 mg or 20 mg for body weight >/=40 kg or <40 kg; n = 93)
Trial: 22562021
Drug: Adalimumab low
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab low dose (20 mg or 10 mg for body weight >/=40 kg or <40 kg; n = 95)
Trial: 15570084
Drug: Tipifarnib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipifarnib (all doses)
Trial: 11213010
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg prednisolone daily in two divided oral doses
Trial: 16671837
Drug: Improvisational music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvisational music therapy
Trial: 4054138
Drug: PY-108-068 75
RxNorm normalized name: KETOCONAZ 2% GEL/ZINC PY 1% SHAMPOO KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PY-108-068 75 mg
Trial: 4054138
Drug: PY-108-068 150
RxNorm normalized name: KETOCONAZ 2% GEL/ZINC PY 1% SHAMPOO KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PY-108-068 150 mg
Trial: 20731496
Drug: Multisystemic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisystemic Therapy for Child Abuse and Neglect (MST‐CAN)
Trial: 29619643
Drug: Enhanced outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced outpatient treatment
Trial: 1590572
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg and flunitrazepam 0.5 mg p.o. given at 10:00 p.m. on the evening prior to surgery
Trial: 1590572
Drug: Famotidine treatment
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famotidine treatment group
Trial: 2070703
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg nocte)
Trial: 20438539
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of sevelamer and calcium carbonate
Trial: 20438539
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of sevelamer and calcium carbonate
Trial: 10470387
Drug: Group P100:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P100: propofol 1% 20 ml/lignocaine 1% 4 ml
Trial: 2013178
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of acute sublingual nitrendipine
Trial: 2013178
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of nitrendipine once daily for 3 weeks
Trial: 6496911
Drug: 5% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lignocaine and prilocaine cream applied for 20 minutes or longer
Trial: 6496911
Drug: 5% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lignocaine and prilocaine cream
Trial: 28900859
Drug: Music used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music used for relaxation and treatment of depression, 12 structured group sessions of 22 min, two times a day for 4 weeks
Trial: 21337773
Drug: Educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program about Ca, PO4 and PTH metabolism
Trial: 17204525
Drug: Mild stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild stimulation regimen using GnRH antagonist co‐treatment (67 patients)
Trial: 17204525
Drug: Conventional high‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional high‐dose exogenous gonadotrophin regimen and GnRH agonist co‐treatment (44 patients)
Trial: 15700748
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml olive oil with high phenolic content
Trial: 15700748
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml olive oil with moderate phenolic content
Trial: 15700748
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml olive oil with low phenolic content
Trial: 9186538
Drug: G-CSF and
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF and 200 IU/kg of EPO (group L)
Trial: 9186538
Drug: G-CSF and
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF and 400 IU/kg of EPO (group H)
Trial: 9186538
Drug: G-CSF alone
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF alone (group C)
Trial: 2418302
Drug: Nicardipine (20-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (20-30 mg three times daily)
Trial: 2418302
Drug: Nicardipine (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (with pindolol as second-step treatment)
Trial: 2418302
Drug: Placebo (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (with pindolol as second-step treatment)
Trial: 26981608
Drug: Comprehensive oral
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive oral health care
Trial: 30746532
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health examination (Control)
Trial: 25299536
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (designed physical therapy program)
Trial: 18812844
Drug: Ropivacaine hydrochloride,
RxNorm normalized name: Ropivacaine Hydrochloride, 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine hydrochloride, 0.2 mg/kg, by submucous infiltration of the proposed incisional site
Trial: 21764706
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication before surgery)
Trial: 12709722
Drug: Itraconazole, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole, 200 mg once daily for 5 days with 80 mg rosuvastatin coadministered on day 4 (trial B)
Trial: 11766002
Drug: Rubella IgG
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubella IgG antibody testing using ELISA technique
Trial: 30587926
Drug: Vardenafil hydrochloride
RxNorm normalized name: Vardenafil Hydrochloride
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vardenafil hydrochloride (20 mg tablets)
Trial: 27783767
Drug: Oral sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sedation with midazolam
Trial: 27783767
Drug: Oral sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sedation with midazolam/ketamine
Trial: 11726454
Drug: No sedative
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No sedative
Trial: 20377476
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg and simvastatin 20 mg/day
Trial: 11324984
Drug: INS365 ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS365 ophthalmic solution (0.5%, 1.0%, 2.0%, 5.0%)
Trial: 11324984
Drug: INS365 ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS365 ophthalmic solution (5.0%)
Trial: 11324984
Drug: INS365 ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS365 ophthalmic solution
Trial: 8433151
Drug: AGM-1470 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AGM-1470 treatment
Trial: 3630929
Drug: Isosorbide-5-mononitrate (IS-5MN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (IS-5MN) 20 mg
Trial: 3630929
Drug: Isosorbide-5-mononitrate (IS-5MN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (IS-5MN) 40 mg
Trial: 12368971
Drug: Daily movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily movement (passive range of motion with gentle compression of both the upper and lower extremities, 5 days per week for 4 weeks)
Trial: 6759814
Drug: Anapsos 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anapsos 120 mg
Trial: 31599965
Drug: Hard water
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard water (> 257 mg L−1 CaCO3)
Trial: 31599965
Drug: Soft water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft water (≤ 257 mg L−1 CaCO3)
Trial: 25929612
Drug: Micafungin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (1 mg/kg for candidiasis, 1 to 3 mg/kg for aspergillosis, up to 6 mg/kg once daily if required)
Trial: 19364294
Drug: EFA supplementation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EFA supplementation (480 mg of linoleic acid and 120 mg of alpha-linolenic acid)
Trial: 10839585
Drug: Abacavir (ABC)
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abacavir (ABC) + Stable Background Therapy (SBG)
Trial: 10839585
Drug: Stable Background
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable Background Therapy (SBG) alone